InMed Pharmaceuticals INM Institutional Ownership

Updated Oct 10, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM) was reported as a holding by 20 institutional investors in 13F filings for the quarter ended June 30, 2026.

• These investors held 50.52% of InMed Pharmaceuticals' outstanding shares at the end of Q2 2026, up from 7.89% in Q1 2026.
• Total holdings of InMed Pharmaceuticals shares rose 744.84% from Q1 2026, and the number of holders rose 185.71% from Q2 2025.
• Looking at the 20 holders of INM individually, 13 added to their positions, 3 reduced their stakes and 4 left their positions unchanged.
• In total, institutional investors held 2.7Mn shares of InMed Pharmaceuticals at the end of Q2 2026, up 2.38Mn from the prior quarter and up 2.69Mn from a year earlier.
• As of June 30, 2026, the biggest holder of InMed Pharmaceuticals was ADAR1 Capital Management, LLC with 800K shares, or 14.98% of shares outstanding.
• Holders that trimmed the most shares of InMed Pharmaceuticals in Q2 2026 while keeping a position were Sabby Management, LLC (-175.29K shares), Citadel Advisors LLC (-20.89K shares) and Two Sigma Securities, LLC (-7.77K shares).
• Per Business Quant data, the 10 largest holders of InMed Pharmaceuticals at the end of Q2 2026 were ADAR1 Capital Management, LLC (800K shares), Vivo Capital, LLC (798.38K shares), Squadron Capital Management LLC (325K shares), Ikarian Capital, LLC (245.03K shares), Ursa Fund Management, LLC (125.8K shares), Montanova Capital, LLC (100K shares), Boothbay Fund Management, LLC (74.24K shares), Sabby Management, LLC (44.97K shares), Jane Street Group, LLC (43.08K shares) and Venrock Adviser, LLC (32.69K shares).